Artykuły w czasopismach na temat „Open Forum Speakers Bureau”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Open Forum Speakers Bureau”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Emanuel, Robyn M., Zhenya Senyak, Archie McCallister, Mary Cotter, Barbara VanHusen, Claire N. Harrison i Ruben A. Mesa. "The MPN Fatigue Project: Stage 1 Results Of The MPN Forum Internet-Based Survey Among 879 MPN Patients". Blood 122, nr 21 (15.11.2013): 1595. http://dx.doi.org/10.1182/blood.v122.21.1595.1595.
Pełny tekst źródłaBaljevic, Muhamed, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge i in. "Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment". Blood 138, Supplement 1 (5.11.2021): 2751. http://dx.doi.org/10.1182/blood-2021-150998.
Pełny tekst źródłaLentzsch, Suzanne, Brea Lipe, Sascha A. Tuchman, Nizar J. Bahlis, William I. Bensinger, Michael Sebag, Heather J. Sutherland i in. "Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)". Blood 138, Supplement 1 (5.11.2021): 1651. http://dx.doi.org/10.1182/blood-2021-150232.
Pełny tekst źródłaRoose, Elien, An-Sofie Schelpe, Edwige Tellier, György Sinkovits, Gilles Kaplanski, Maelle Le Besnerais, Ilaria Mancini i in. "Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology". Blood 132, Supplement 1 (29.11.2018): 222. http://dx.doi.org/10.1182/blood-2018-99-113762.
Pełny tekst źródłaStein, Eytan M., Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Michael R. Savona, Anthony S. Stein, Richard M. Stone i in. "Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation". Blood 138, Supplement 1 (5.11.2021): 1276. http://dx.doi.org/10.1182/blood-2021-146507.
Pełny tekst źródłaPeyvandi, Flora, Bruce A. Schwartz i Sigurd Knaub. "Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency". Blood 132, Supplement 1 (29.11.2018): 2501. http://dx.doi.org/10.1182/blood-2018-99-116572.
Pełny tekst źródłaJurczak, Wojciech, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda i Pier Luigi Zinzani. "BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)". Blood 138, Supplement 1 (5.11.2021): 3732. http://dx.doi.org/10.1182/blood-2021-145938.
Pełny tekst źródłaCarlo-Stella, Carmelo, Pier Luigi Luigi Zinzani, Anna Sureda, Luís Francisco Araújo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh i in. "A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma". Blood 138, Supplement 1 (5.11.2021): 4362. http://dx.doi.org/10.1182/blood-2021-148431.
Pełny tekst źródłaJurczak, Wojciech, Pier Luigi Zinzani, Georg Hess, Gianluca Gaidano, Mariano Provencio, Zsolt Nagy, Tadeusz Robak i in. "A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis". Blood 134, Supplement_1 (13.11.2019): 4078. http://dx.doi.org/10.1182/blood-2019-124297.
Pełny tekst źródłaPeyvandi, Flora, Bruce A. Schwartz i Sigurd Knaub. "Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study". Blood 132, Supplement 1 (29.11.2018): 2502. http://dx.doi.org/10.1182/blood-2018-99-116440.
Pełny tekst źródłaKornauth, Christoph, Tea Pemovska, Gregory Ian Vladimer, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner i in. "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial". Blood 136, Supplement 1 (5.11.2020): 2–4. http://dx.doi.org/10.1182/blood-2020-140831.
Pełny tekst źródłaYoung, Guy, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin i in. "HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors". Blood 130, Suppl_1 (7.12.2017): 85. http://dx.doi.org/10.1182/blood.v130.suppl_1.85.85.
Pełny tekst źródłaOldenburg, Johannes, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria i Mark Reding. "Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study". Blood 134, Supplement_1 (13.11.2019): 4943. http://dx.doi.org/10.1182/blood-2019-128140.
Pełny tekst źródłaMiesbach, Wolfgang A., Giovanni Di Minno, Elena Santagostino, Dr Klamroth, Inga Bayh, Amaryllis Soto i Cedric Hermans. "Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data". Blood 134, Supplement_1 (13.11.2019): 1117. http://dx.doi.org/10.1182/blood-2019-128486.
Pełny tekst źródłaKojima, S., T. Iwamoto, Y. Kobayashi, M. Kato, F. Takizawa, T. Ida, Y. Toda i in. "POS0572 IMMUNOGENICITY AND SAFETY OF ADJUVANTED RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS". Annals of the Rheumatic Diseases 82, Suppl 1 (30.05.2023): 554.2–555. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1608.
Pełny tekst źródłaPeyvandi, Flora, Spero R. Cataland, Marie Scully, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian i in. "Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura". Blood 132, Supplement 1 (29.11.2018): 373. http://dx.doi.org/10.1182/blood-2018-99-112125.
Pełny tekst źródłaRaje, Noopur, Paul Richardson, Parameswaran N. Hari, Anuj Mahindra, Sarah Kaster, Christine Connolly, Linda Rivera i in. "An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma." Blood 114, nr 22 (20.11.2009): 3856. http://dx.doi.org/10.1182/blood.v114.22.3856.3856.
Pełny tekst źródłaChavez, Julio C., Neta Goldschmidt, Felipe Samaniego, Tomasz Wrobel, Federica Cavallo, Gustavo Fonseca, Sung-Soo Yoon i in. "The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial". Blood 138, Supplement 1 (5.11.2021): 45. http://dx.doi.org/10.1182/blood-2021-147425.
Pełny tekst źródłaNoy, Ariela, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher Flowers, Franck Morschhauser, Graham P. Collins i in. "Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study". Blood 128, nr 22 (2.12.2016): 1213. http://dx.doi.org/10.1182/blood.v128.22.1213.1213.
Pełny tekst źródłaKremer Hovinga, Johanna A., Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Javier De La Rubia i in. "Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study". Blood 132, Supplement 1 (29.11.2018): 3744. http://dx.doi.org/10.1182/blood-2018-99-112177.
Pełny tekst źródłaSiegel, David S., Gary J. Schiller, Christy J. Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous i in. "Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial". Blood 136, Supplement 1 (5.11.2020): 16–17. http://dx.doi.org/10.1182/blood-2020-134189.
Pełny tekst źródłaDreyling, Martin, Panayiotis Panayiotidis, George A. Follows, Luigina Mollica, Arnon Nagler, Muhit Özcan, Armando Santoro i in. "Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma". Blood 134, Supplement_1 (13.11.2019): 1531. http://dx.doi.org/10.1182/blood-2019-121932.
Pełny tekst źródłaPerkins, Andrew Charles, Kate Burbury, Thomas Lehmann, David M. Ross, Andreas Reiter, Vikas Gupta, Claire Harrison i in. "Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis". Blood 136, Supplement 1 (5.11.2020): 52–53. http://dx.doi.org/10.1182/blood-2020-140408.
Pełny tekst źródłaZinzani, Pier Luigi, Armando Santoro, Luigina Mollica, Sirpa Leppä, George A. Follows, Georg Lenz, Won Seog Kim i in. "Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies". Blood 134, Supplement_1 (13.11.2019): 4009. http://dx.doi.org/10.1182/blood-2019-131779.
Pełny tekst źródłaDadwal, Sanjeet S., Michael Shuster, Gary Douglas Myers, Keith Boundy, Marshelle Warren, Elizabeth Stoner, Thuy Truong i Joshua A. Hill. "Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial". Blood 138, Supplement 1 (5.11.2021): 1760. http://dx.doi.org/10.1182/blood-2021-152553.
Pełny tekst źródłaPaschka, Peter, Hervé Dombret, Xavier Thomas, Christian Recher, Sylvain Chantepie, Pau Montesinos Fernandez, Evelyn Acuña-Cruz i in. "Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls". Blood 136, Supplement 1 (5.11.2020): 18–19. http://dx.doi.org/10.1182/blood-2020-136957.
Pełny tekst źródłaKumagai, Takashi, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi i in. "Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial". Blood 138, Supplement 1 (5.11.2021): 3601. http://dx.doi.org/10.1182/blood-2021-149483.
Pełny tekst źródłaStilgenbauer, Stephan, Francesc Bosch, Véronique Leblond, Osman Ilhan, Jens Kisro, Béatrice Mahé, Eva Mikuskova i in. "Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy". Blood 134, Supplement_1 (13.11.2019): 3035. http://dx.doi.org/10.1182/blood-2019-123419.
Pełny tekst źródłaShapiro, Amy, Giancarlo Castaman, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, Silva Zupancic-Salek i Victor Jimenez-Yuste. "Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial". Blood 134, Supplement_1 (13.11.2019): 1139. http://dx.doi.org/10.1182/blood-2019-122809.
Pełny tekst źródłaJurczak, Wojciech, Pier Luigi Luigi Zinzani, David Cunningham, Michel Azoulay, Wenying Huang, Weiming Xu i Vincent Ribrag. "Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)". Blood 138, Supplement 1 (5.11.2021): 2430. http://dx.doi.org/10.1182/blood-2021-148015.
Pełny tekst źródłaMato, Anthony R., William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu i in. "BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)". Blood 138, Supplement 1 (5.11.2021): 3742. http://dx.doi.org/10.1182/blood-2021-145936.
Pełny tekst źródłaUsmani, Saad Z., Maria-Victoria Mateos, Hareth Nahi, Sebastian Grosicki, Vladimir I. Vorobyev, Ivan Spicka, Vania T. M. Hungria i in. "Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update". Blood 134, Supplement_1 (13.11.2019): 1865. http://dx.doi.org/10.1182/blood-2019-122765.
Pełny tekst źródłaMatsumura, Itaru, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko i in. "Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212". Blood 136, Supplement 1 (5.11.2020): 40–41. http://dx.doi.org/10.1182/blood-2020-134168.
Pełny tekst źródłaHampton, Kingsley, Pratima Chowdary, Scott Dunkley, Silke Ehrenforth, Lotte Jacobsen, Anne T. Neff, Elena Santagostino i in. "First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a". Blood 126, nr 23 (3.12.2015): 2283. http://dx.doi.org/10.1182/blood.v126.23.2283.2283.
Pełny tekst źródłaNeelapu, Sattva S., Mohamed A. Kharfan-Dabaja, Olalekan O. Oluwole, Patel Krish, Ran Reshef, Peter A. Riedell, Parveen Shiraz i in. "A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)". Blood 134, Supplement_1 (13.11.2019): 4093. http://dx.doi.org/10.1182/blood-2019-126369.
Pełny tekst źródłaBailey, Neil, Tenzin Tsomo, Jennie Szeto, William I. Bensinger, Daniel Egan, Livia Hegerova, Raya Mawad i in. "Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma". Blood 136, Supplement 1 (5.11.2020): 34. http://dx.doi.org/10.1182/blood-2020-141074.
Pełny tekst źródłaElsawy, Mahmoud, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman i in. "Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)". Blood 138, Supplement 1 (5.11.2021): 430. http://dx.doi.org/10.1182/blood-2021-147598.
Pełny tekst źródłaStewart, A. Keith, S. Vincent Rajkumar, Meletios A. Dimopoulos, Tamás Masszi, Ivan Spicka, Albert Oriol, Roman Hájek i in. "Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study". Blood 124, nr 21 (6.12.2014): 79. http://dx.doi.org/10.1182/blood.v124.21.79.79.
Pełny tekst źródłaBussel, James B., Francesco Rodeghiero, Roger M. Lyons, Barry Firstenberg, Joanne Joseph, Craig M. Kessler, Louis Terriou, Roberto Stasi, Paul Chang i Susie Jun. "Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases",. Blood 118, nr 21 (18.11.2011): 3281. http://dx.doi.org/10.1182/blood.v118.21.3281.3281.
Pełny tekst źródłaZinzani, Pier Luigi, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny i in. "Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial". Blood 136, Supplement 1 (5.11.2020): 34–35. http://dx.doi.org/10.1182/blood-2020-134851.
Pełny tekst źródłaVannucchi, Alessandro M., Heinz Gisslinger, Claire N. Harrison, Haifa Kathrin Al-Ali, Ester Pungolino, Jean-Jacques Kiladjian, Francoise Boyer-Perrard i in. "EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline". Blood 126, nr 23 (3.12.2015): 2817. http://dx.doi.org/10.1182/blood.v126.23.2817.2817.
Pełny tekst źródłaSantagostino, Elena, Kathelijn Fischer, Christoph Koenigs, Claudia Djambas Khayat, Samantha Lucas, Blanca Salazar, Andres Brainsky, Thomas Chung, Brahm Goldstein i Johnny Mahlangu. "Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)". Blood 134, Supplement_1 (13.11.2019): 162. http://dx.doi.org/10.1182/blood-2019-123981.
Pełny tekst źródłaLonial, Sagar, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan i in. "Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma". Blood 138, Supplement 1 (5.11.2021): 2742. http://dx.doi.org/10.1182/blood-2021-148385.
Pełny tekst źródłaChiaretti, Sabina, Renato Bassan, Antonella Vitale, Loredana Elia, Alfonso Piciocchi, Cristina Puzzolo, Martina Canichella i in. "Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial". Blood 134, Supplement_1 (13.11.2019): 740. http://dx.doi.org/10.1182/blood-2019-128759.
Pełny tekst źródłaDucore, Jonathan M., Shadan Lalezari, Elena Santagostino, Sanjay P. Ahuja, Monika Maas Enriquez, Claudia Tueckmantel i Mark Reding. "Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study". Blood 134, Supplement_1 (13.11.2019): 1129. http://dx.doi.org/10.1182/blood-2019-123947.
Pełny tekst źródłaJimenez-Yuste, Victor, Midori Shima, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron i Gallia G. Levy. "Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)". Blood 130, Suppl_1 (7.12.2017): 86. http://dx.doi.org/10.1182/blood.v130.suppl_1.86.86.
Pełny tekst źródłaMackensen, Andreas, Linda Hanssens, Matthias Stelljes, Wolfgang A. Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner i in. "A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts". Blood 138, Supplement 1 (5.11.2021): 3836. http://dx.doi.org/10.1182/blood-2021-152452.
Pełny tekst źródłaZinzani, Pier Luigi, Vincent Delwail, Shankara Paneesha, Simon Rule, Alejandro Martin Garcia-Sancho, Ana Marin-Niebla, Gilles Salles i in. "Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)". Blood 136, Supplement 1 (5.11.2020): 43–44. http://dx.doi.org/10.1182/blood-2020-134609.
Pełny tekst źródłaÁlvarez Roman, Teresa, Elena Monzón Manzano, Ihosvany Fernandez-Bello, Mónica Martín, María Isabel Rivas Pollmar, Raul Justo Sanz, Sara García Barcenilla i in. "Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein". Blood 134, Supplement_1 (13.11.2019): 4929. http://dx.doi.org/10.1182/blood-2019-127878.
Pełny tekst źródłaMehta, Amitkumar, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane i in. "Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)". Blood 136, Supplement 1 (5.11.2020): 22–23. http://dx.doi.org/10.1182/blood-2020-134872.
Pełny tekst źródła